Meglutol-d3
(Synonyms: 氘代3-羟基-3-甲基(D3)) 目录号 : GC49486An internal standard for the quantification of meglutol
Cas No.:59060-36-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Meglutol-d3 is intended for use as an internal standard for the quantification of meglutol by GC- or LC-MS. Meglutol is an HMG-CoA reductase inhibitor (IC50 = 4 nM) and antimetabolite of mevalonic acid.1 Dietary administration of meglutol (10, 20, and 30 mg/kg per day) reduces serum total cholesterol levels in normal rats, as well as reduces them in high-cholesterol fed and hypercholesterolemic rats when administered in the drinking water at a dose of 50 mg/kg per day.2 It also reduces serum levels of cholesterol, triglycerides, phospholipids, and free fatty acids, as well as the severity of aortic atherosclerotic lesions, in a rabbit model of atherosclerosis induced by a high-cholesterol diet when administered at a dose of 25 mg/animal per day.3 Intracerebroventricular administration of meglutol (0.5 µmol/g) induces lipid peroxidation and decreases the activity of glutathione peroxidase in the cerebral cortex of one-day old rat pups.4 Meglutol accumulates in the tissues and fluids of patients with HMG-CoA lyase deficiency, a disorder characterized by metabolic acidosis, hypoglycemia, and lethargy.4
1.Medina-Franco, J.L., LÓpez-Vallejo, F., RodrÍguez-Morales, S., et al.Molecular docking of the highly hypolipidemic agent α-asarone with the catalytic portion of HMG-CoA reductaseBioorg. Med. Chem. Lett.15(4)989-994(2005) 2.Beg, Z.H., and Siddiqi, M.Hypocholesterolemic effect of 3-hydroxy-3-methylglutaric acidExperientia23(5)380(1967) 3.Lupien, P.J., Tremblay, M., and Beg, Z.H.3-Hydroxy-3-methylglutaric acid: Protective action in experimental atherosclerosis in rabbitsAtherosclerosis18(3)407-416(1973) 4.da Rosa, M.S., da Rosa-Junior, N.T., Parmeggiani, B., et al.3-Hydroxy-3-methylglutaric acid impairs redox and energy homeostasis, mitochondrial dynamics, and endoplasmic reticulum-mitochondria crosstalk in rat brainNeurotox. Res.37(2)314-325(2020)
Cas No. | 59060-36-5 | SDF | Download SDF |
别名 | 氘代3-羟基-3-甲基(D3) | ||
Canonical SMILES | OC(CC(C([2H])([2H])[2H])(O)CC(O)=O)=O | ||
分子式 | C6H7D3O5 | 分子量 | 165.2 |
溶解度 | DMF: 30mg/mL,DMSO: 30mg/mL,Ethanol: 30mg/mL,PBS (pH 7.2): 10mg/mL | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 6.0533 mL | 30.2663 mL | 60.5327 mL |
5 mM | 1.2107 mL | 6.0533 mL | 12.1065 mL |
10 mM | 0.6053 mL | 3.0266 mL | 6.0533 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。